Conference Reports for NATAP

Back

2019 AASLD/EASL HCV Special Conference 01-02 February 2019, Miami, FL     Homeless shelter client and provider barriers and facilitators to implementing HCV testing, access, and linkage to care in the homeless population - (02/07/19)   Universal access to Direct Acting Antiviral treatment and high engagement in care results in a major drop in hepatitis C viremia in people who inject drugs Results from TraPHepCin Iceland (Treatment as Prevention) poster - Miami AASLD-EASL HCV Special Conference 2/1/19 - (02/07/19)   Homeless Shelter Client and Provider Barriers and Facilitators To Implementing HCV Testing, Access, and Linkage To Care In The Homeless Population - (02/06/19)   Is There a Need to Re-Focus our Efforts for Hepatitis C Screening Away from Baby Boomers? 23% HCV+ in Rural Drug Users Pennsylvania - (02/05/19)   Worldwide HCV Epidemiology and Impact of Treatment - (02/05/19)   Hepatitis C care continuum at a safety-net health system among adults enrolled in probations in Denver, Colorado - AASLD-EASL HCV Special Conference Miami 2019 Feb 1 - (02/05/19)   Universal Access to Direct Acting Antiviral Treatment and High Engagement in Care Results in a Major Drop in Hepatitis C Viremia in People Who Inject DrugsResults from TraPHepCin Iceland (Treatment as Prevention) - AASLD-EASL HCV Special Conference Miami 2/1/19 - (02/05/19)   The Intersection Between the Opioid Epidemic and HCV Infection: An Opportunity to Save Lives with HCV Cure and Overdose Prevention - (02/04/19)   Commitment to Global Elimination of Hepatitis C Virus - (02/04/19)   The Cost of HCV Elimination - AASLD-EASL HCV Special Conference Miami 2/1/19 - (02/04/19)   Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - (02/04/19)   Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - AASLD/EASL HCV Special Conference Miami 2/1/19 - (02/04/19)   Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis - AASLD-EASL Special HCV Conference Miami - (02/04/19)   Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - AASLD/EASL Special HCV Conference Miami - (02/04/19)   Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - (02/04/19)